A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia

• Published in: Advances in therapy Vol. 41; no. 7; pp. 2936 - 2952
• Main Authors: Kim, Heesun, Ryu, Choongho, Lee, Mase, Lee, Kyeong-Ryoon, Kim, Juhee
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.07.2024
• Subjects: 5-alpha Reductase Inhibitors - administration & dosage; 5-alpha Reductase Inhibitors - adverse effects; 5-alpha Reductase Inhibitors - pharmacokinetics; 5-alpha Reductase Inhibitors - pharmacology; Adult; Alopecia - drug therapy; Cardiology; Delayed-Action Preparations; Dihydrotestosterone - administration & dosage; Dihydrotestosterone - blood; Dihydrotestosterone - pharmacokinetics; Endocrinology; Finasteride - administration & dosage; Finasteride - adverse effects; Finasteride - pharmacokinetics; Humans; Injections, Subcutaneous; Internal Medicine; Male; Medicine; Medicine & Public Health; Microspheres; Middle Aged; NCT; NCT04945226; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Testosterone - blood; Testosterone - pharmacokinetics; Young Adult; Dihydrotestosterone; Finasteride; IVL3001; AGA; Hair loss; Long-acting injectables
• DOI: 10.1007/s12325-024-02890-1
• ISSN: 0741-238X; 1865-8652

Introduction Hair loss is driven by multiple factors, including genetics. Androgenetic alopecia (AGA) is a condition in which treatments necessitate prolonged compliance with prescribed medications. We have developed IVL3001, a long-acting injectable (LAI) formulation of finasteride encapsulated within poly lactic-co-glycolic acid microspheres, to enhance the efficacy of the finasteride and to achieve consistent positive outcomes in adults. An open-label, sequential, single-dose phase I clinical trial was designed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) of IVL3001. Methods A total of 40 non-smoking, healthy adult males were divided into three cohorts where the IVL3001 group received a single subcutaneous injection of 12–36 mg IVL3001 and 1 mg finasteride (Propecia ® ) once daily for 28 days. The plasma concentrations of finasteride, dihydrotestosterone (DHT), and testosterone were measured using liquid chromatography–tandem mass spectrometry. The tolerability of the injections was assessed, and compartment models were developed to predict the effective dose and assess PK/PD profiles. Results IVL3001 and finasteride 1 mg tablets were well tolerated. IVL3001 showed consistent plasma concentrations without bursts or fluctuations. Consistent with its mechanism of action, IVL3001 reduced DHT levels. Simulation data showed that the administration of 12–36 mg of IVL3001 every 4 weeks achieved plasma concentrations similar to finasteride, with comparable DHT reduction. Conclusion The present study represents the first clinical trial to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD), and tolerability of finasteride long-acting injectables (LAI) in adults. The rapid onset of action sustained effective drug concentration and the prolonged half-life of IVL3001 suggest that it offers multiple benefits over conventional oral formulations in terms of therapeutic response and compliance. Trial Registration ClinicalTrials.gov identifier, NCT04945226.